Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels

Mao Li, Zhuo Zhang, Donald L. Hill, Xinbin Chen, Hui Wang, Ruiwen Zhang

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between -132 and +33 in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiqiuitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis in vitro and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects.

Original languageEnglish (US)
Pages (from-to)8200-8208
Number of pages9
JournalCancer Research
Volume65
Issue number18
DOIs
StatePublished - Sep 15 2005
Externally publishedYes

Fingerprint

Isoflavones
Genistein
Oncogenes
Down-Regulation
Colonic Neoplasms
Prostatic Neoplasms
Apoptosis
Breast Neoplasms
Cell Line
Neoplasms
Heterografts
Protein-Tyrosine Kinases
Breast
Fibroblasts
Epithelial Cells
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. / Li, Mao; Zhang, Zhuo; Hill, Donald L.; Chen, Xinbin; Wang, Hui; Zhang, Ruiwen.

In: Cancer Research, Vol. 65, No. 18, 15.09.2005, p. 8200-8208.

Research output: Contribution to journalArticle

Li, Mao ; Zhang, Zhuo ; Hill, Donald L. ; Chen, Xinbin ; Wang, Hui ; Zhang, Ruiwen. / Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. In: Cancer Research. 2005 ; Vol. 65, No. 18. pp. 8200-8208.
@article{f1039ea9c5014d36b5c17c52905fd0ff,
title = "Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels",
abstract = "Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between -132 and +33 in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiqiuitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis in vitro and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects.",
author = "Mao Li and Zhuo Zhang and Hill, {Donald L.} and Xinbin Chen and Hui Wang and Ruiwen Zhang",
year = "2005",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-05-1302",
language = "English (US)",
volume = "65",
pages = "8200--8208",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels

AU - Li, Mao

AU - Zhang, Zhuo

AU - Hill, Donald L.

AU - Chen, Xinbin

AU - Wang, Hui

AU - Zhang, Ruiwen

PY - 2005/9/15

Y1 - 2005/9/15

N2 - Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between -132 and +33 in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiqiuitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis in vitro and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects.

AB - Although genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate, the mechanisms of action are not fully understood. Herein we report novel mechanisms whereby genistein down-regulates the MDM2 oncogene, perhaps explaining some of its anticancer activities. In a dose- and time-dependent manner, genistein reduced MDM2 protein and mRNA levels in human cell lines of breast, colon, and prostate cancer; primary fibroblasts; and breast epithelial cells. The inhibitory effects were found at both transcriptional and posttranslational levels and were independent of tyrosine kinase pathways. We found that the NFAT transcription site in the region between -132 and +33 in the MDM2 P2 promoter was responsive to genistein. At the posttranslational level, genistein induced ubiqiuitination of MDM2, which led to its degradation. Additionally, genistein induced apoptosis and G2 arrest and inhibited proliferation in a variety of human cancer cell lines, regardless of p53 status. We further showed that MDM2 overexpression abrogated genistein-induced apoptosis in vitro and that genistein inhibited MDM2 expression and tumor growth in PC3 xenografts. In conclusion, genistein directly down-regulates the MDM2 oncogene, representing a novel mechanism of its action that may have implications for its chemopreventive and chemotherapeutic effects.

UR - http://www.scopus.com/inward/record.url?scp=24944458421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944458421&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1302

DO - 10.1158/0008-5472.CAN-05-1302

M3 - Article

C2 - 16166295

AN - SCOPUS:24944458421

VL - 65

SP - 8200

EP - 8208

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -